Hematopathology — MCQs

Hematopathology Indian Medical PG Practice Questions and MCQs

Question 1041: Oxidative injury of the red blood cells leading to hemolysis is associated with which of the following clinical conditions?

A. G6PD deficiency (Correct Answer)
B. Hereditary spherocytosis
C. Sickle cell anemia
D. Hemophilia

Explanation: **Explanation:** **G6PD Deficiency (Correct Answer):** Glucose-6-Phosphate Dehydrogenase (G6PD) is the rate-limiting enzyme in the Hexose Monophosphate (HMP) shunt, which is the sole source of **NADPH** in red blood cells [1]. NADPH is essential for maintaining a pool of **reduced glutathione**, which neutralizes reactive oxygen species (ROS) like hydrogen peroxide. In G6PD deficiency, oxidative stress (triggered by fava beans, infections, or drugs like Primaquine and Sulfa) leads to the oxidation of hemoglobin. This results in the formation of **Heinz bodies**, which damage the RBC membrane, leading to intravascular and extravascular hemolysis [2]. **Why other options are incorrect:** * **Hereditary Spherocytosis:** This is a **membranopathy** caused by defects in RBC cytoskeleton proteins (Ankyrin, Spectrin, or Band 3) [1]. Hemolysis occurs due to the loss of membrane surface area and splenic sequestration, not oxidative injury [3]. * **Sickle Cell Anemia:** This is a **hemoglobinopathy** caused by a point mutation (Glu → Val) in the β-globin chain [1]. Hemolysis is triggered by **polymerization of HbS** under deoxygenated conditions, leading to "sickling" and vaso-occlusion. * **Hemophilia:** This is a **coagulation disorder** (Factor VIII or IX deficiency) characterized by bleeding tendencies (e.g., hemarthrosis). It does not involve RBC hemolysis. **NEET-PG High-Yield Pearls:** * **Peripheral Smear:** Look for **Heinz bodies** (supravital stains like Crystal Violet) and **Bite cells** (degmacytes) formed by splenic macrophages "plucking" out Heinz bodies [2]. * **Inheritance:** G6PD deficiency is **X-linked recessive**. * **Protection:** G6PD deficiency provides a protective advantage against *Plasmodium falciparum* malaria. * **Timing:** Never test G6PD levels during an acute hemolytic episode, as young reticulocytes have higher enzyme levels, potentially yielding a **false-negative** result [2]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, p. 638. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, pp. 642-643. [3] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 597-598.

Question 1042: Which of the following is a poor prognostic factor in Acute Myeloid Leukemia (AML)?

A. Monosomy (Correct Answer)
B. Deletion of X or Y chromosome
C. t (8; 21) translocation
D. Nucleophosphin mutation

Explanation: ### Explanation In Acute Myeloid Leukemia (AML), cytogenetic and molecular abnormalities are the most significant predictors of clinical outcome and treatment response [1]. **1. Why Monosomy is the Correct Answer:** Monosomies (loss of an entire chromosome), particularly of **chromosomes 5 or 7**, or the presence of a **complex karyotype** (≥3 abnormalities), are classified as **adverse/poor prognostic factors**. These are often associated with therapy-related AML or AML evolving from Myelodysplastic Syndrome (MDS). They typically show poor response to standard induction chemotherapy and high relapse rates. **2. Analysis of Incorrect Options:** * **Deletion of X or Y chromosome:** These are considered **isolated secondary changes** and do not carry an adverse prognosis. In many cases, the loss of a sex chromosome is considered a "neutral" or "favorable" finding compared to complex karyotypes. * **t(8;21):** This translocation involves the *RUNX1-RUNX1T1* genes. It is a hallmark of **favorable prognosis** AML (specifically AML-M2 in the FAB classification) and generally responds well to cytarabine-based therapy [1]. * **Nucleophosmin (NPM1) mutation:** In the absence of *FLT3-ITD* mutations, an *NPM1* mutation is a **favorable prognostic marker** [1]. It is one of the most common genetic alterations in adult AML with a normal karyotype. **Clinical Pearls for NEET-PG:** * **Favorable Prognosis:** t(8;21), inv(16), t(15;17) [APML], and isolated *NPM1* or *CEBPA* mutations [1]. * **Poor Prognosis:** Monosomy 5/7, del(5q), 11q23 (MLL gene) rearrangements, and *FLT3-ITD* mutations [1]. * **APML (t15;17):** While it has a high risk of early mortality due to DIC, it has the **best long-term prognosis** with ATRA and Arsenic Trioxide therapy. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus, pp. 620-621.

Question 1043: The AB blood group antigen is also known as the ... factor?

A. Duffy
B. Landsteiner (Correct Answer)
C. Rhesus
D. Lutheran

Explanation: **Explanation:** The correct answer is **Landsteiner**. **1. Why Landsteiner is correct:** The ABO blood group system was discovered by **Karl Landsteiner** in 1900. He identified the A, B, and O antigens on the surface of red blood cells and formulated "Landsteiner’s Law," which states that if an agglutinogen (antigen) is present on the RBCs, the corresponding agglutinin (antibody) must be absent from the serum [1]. Because of his pioneering work in defining the major blood groups, the AB antigens are eponymously referred to as the Landsteiner factor. He was awarded the Nobel Prize in Physiology or Medicine in 1930 for this discovery. **2. Why other options are incorrect:** * **Duffy (Option A):** This is a minor blood group system (Fy antigens). It is clinically significant because the Duffy antigen acts as a receptor for *Plasmodium vivax*; individuals who are Duffy-negative (common in African populations) are resistant to vivax malaria. * **Rhesus (Option C):** Also discovered by Landsteiner (along with Alexander Wiener), the Rh factor (D antigen) is a separate system from ABO [1]. It is the primary cause of Hemolytic Disease of the Newborn (HDN) [1]. * **Lutheran (Option D):** This is another minor blood group system (Lu antigens) located on chromosome 19, primarily involved in cell adhesion. **High-Yield Clinical Pearls for NEET-PG:** * **Universal Donor:** O negative (no A, B, or Rh antigens). * **Universal Recipient:** AB positive (no anti-A, anti-B, or anti-D antibodies). * **Bombay Blood Group:** Lacks the H-antigen (genotype hh). These individuals phenotypically test as 'O' but have potent anti-H antibodies, making them compatible only with other Bombay group donors. * **Inheritance:** ABO blood groups follow **codominance**. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 627-628.

Question 1044: Spontaneous bleeding usually occurs when the platelet count falls below which value?

A. 20,000/uL (Correct Answer)
B. 50,000/uL
C. 100,000/uL
D. 120,000/uL

Explanation: **Explanation:** The normal platelet count ranges from **150,000 to 450,000/µL**. Thrombocytopenia is defined as a count below 150,000/µL. However, the risk of bleeding does not correlate linearly with the count until it reaches critical thresholds. * **Why 20,000/µL is correct:** This is considered the critical threshold for **spontaneous bleeding** [3]. When counts fall below this level, the integrity of the microvasculature is compromised [1], leading to petechiae, ecchymoses, and potentially fatal intracranial or gastrointestinal hemorrhages, even in the absence of trauma [2]. **Analysis of Incorrect Options:** * **50,000/µL:** At this level, patients are generally asymptomatic but may experience excessive bleeding following **significant trauma or major surgery**. Spontaneous bleeding is rare at this count. * **100,000/µL:** This is a mild reduction. Hemostasis is typically adequate, and patients can undergo most surgical procedures without increased risk of hemorrhage. * **120,000/µL:** This is near the lower limit of normal. It has no clinical significance regarding bleeding risk unless there is an associated functional platelet defect. **High-Yield Clinical Pearls for NEET-PG:** * **Safe for Major Surgery:** Usually >50,000/µL. * **Safe for Spinal/Neuro Surgery:** Usually >100,000/µL. * **Prophylactic Platelet Transfusion:** Generally indicated in stable patients when the count drops below **10,000/µL** to prevent spontaneous bleeding. * **Bleeding Time (BT):** This is the clinical test for platelet function; it remains normal until the count falls below 100,000/µL. * **Wet Purpura:** The presence of blood blisters in the oral mucosa is a warning sign of life-threatening thrombocytopenia. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Hemodynamic Disorders, Thromboembolic Disease, and Shock, p. 132. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 620-621. [3] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 619-620.

Question 1045: Which of the following is not a B cell neoplasm?

A. Hairy cell leukemia
B. Mycosis fungoides (Correct Answer)
C. Mantle cell lymphoma
D. Burkitt's lymphoma

Explanation: **Explanation:** The correct answer is **Mycosis fungoides** because it is a **T-cell neoplasm**, specifically a Cutaneous T-Cell Lymphoma (CTCL) derived from mature CD4+ helper T-cells [1]. It characteristically involves the skin, progressing through patch, plaque, and tumor stages [2], and is histologically defined by **Pautrier’s microabscesses** (intraepidermal clusters of neoplastic T-cells) [3]. **Analysis of Incorrect Options:** * **Hairy Cell Leukemia (HCL):** A mature B-cell neoplasm characterized by "hairy" cytoplasmic projections [5]. It is positive for B-cell markers (CD19, CD20) and specific markers like **CD103, CD11c, and CD25**. * **Mantle Cell Lymphoma (MCL):** A B-cell neoplasm arising from the follicular mantle zone [4]. It is associated with the **t(11;14)** translocation, leading to overexpression of **Cyclin D1**. * **Burkitt’s Lymphoma:** A highly aggressive B-cell non-Hodgkin lymphoma linked to the **t(8;14)** translocation and **c-MYC** overexpression. It classically shows a "starry-sky" appearance on histology. **High-Yield NEET-PG Pearls:** 1. **Sezary Syndrome:** The leukemic phase of Mycosis fungoides, characterized by erythroderma, lymphadenopathy, and "cerebriform" nuclei (Sezary cells) in the peripheral blood [1]. 2. **TRAP Stain:** Historically used for Hairy Cell Leukemia, though **Annexin A1** is now considered the most specific marker. 3. **B-cell Markers:** CD19, CD20, CD21, CD22, and CD79a [4]. 4. **T-cell Markers:** CD2, CD3, CD4, CD5, CD7, and CD8 [4]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus, pp. 613-614. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Skin, p. 1162. [3] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Diseases Of The Urinary And Male Genital Tracts, pp. 564-565. [4] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus, pp. 596-598. [5] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus, pp. 612-613.

Question 1046: Auer rods are characteristic features of which subtype of acute myeloid leukemia (AML)?

A. AML M0
B. AML M3 (Correct Answer)
C. AML M5
D. AML M7

Explanation: **Explanation:** **Auer rods** are needle-like, azurophilic cytoplasmic inclusions formed by the fusion of primary granules (lysosomes) containing peroxidase. Their presence is a pathognomonic hallmark of **Acute Myeloid Leukemia (AML)**, specifically indicating a myeloid lineage [1]. **Why AML M3 is the correct answer:** While Auer rods can be seen in several AML subtypes (M1, M2, M3, and M4), they are most characteristic and numerous in **AML M3 (Acute Promyelocytic Leukemia)**. In M3, cells often contain bundles of Auer rods known as **"faggot cells"** [1]. These rods are rich in tissue factor; when the cells are lysed (either naturally or by chemotherapy), they release these contents, triggering **Disseminated Intravascular Coagulation (DIC)**, a critical clinical emergency associated with M3 [1]. **Analysis of Incorrect Options:** * **AML M0 (Undifferentiated):** These are primitive blasts that lack morphological and cytochemical evidence of differentiation; therefore, Auer rods are absent. * **AML M5 (Monocytic):** This subtype typically shows monocytic differentiation (monoblasts/promonocytes) [1]. Auer rods are rarely seen in pure monocytic lineages. * **AML M7 (Megakaryoblastic):** This subtype involves platelet precursors. Auer rods are never found in M7 as they are specific to the granulocytic lineage. **High-Yield NEET-PG Pearls:** * **Genetics of M3:** Associated with **t(15;17)**, involving the *PML-RARA* fusion gene [1]. * **Treatment:** Managed with **ATRA** (All-trans retonic acid) and Arsenic Trioxide, which force the maturation of promyelocytes. * **Staining:** Auer rods are strongly **Myeloperoxidase (MPO) positive**. * **Clinical Warning:** Always screen for DIC in a patient with suspected AML M3 [1]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus, pp. 620-622.

Question 1047: Which anticoagulant is the preferred choice for use in a blood bank?

A. Calcium oxalate
B. Heparin solution
C. Acid citrate dextrose solution (Correct Answer)
D. Sodium fluoride

Explanation: **Explanation:** The primary goal of a blood bank anticoagulant is not only to prevent clotting but also to preserve the viability and metabolic function of red blood cells (RBCs) for extended storage. **Why Acid Citrate Dextrose (ACD) is correct:** ACD is a standard preservative solution used in blood banking. It works through two main components: * **Citrate:** Acts as the anticoagulant by chelating (binding) ionized calcium, which is a necessary cofactor (Factor IV) in the coagulation cascade. * **Dextrose (Glucose):** Provides a substrate for ATP production via anaerobic glycolysis, maintaining the RBC membrane integrity and pump function during storage. * **Acid (Citric Acid):** Lowers the pH, which helps in better preservation of the cells. (Note: Modern blood banks often use CPD or CPDA-1, which are improved versions of ACD). **Why other options are incorrect:** * **Calcium Oxalate:** It is an anticoagulant that precipitates calcium. However, it is **toxic** and cannot be infused into a patient, making it unsuitable for blood transfusion. * **Heparin:** While a potent anticoagulant (activates Antithrombin III), it is not used in blood banks because it is expensive, has a short half-life (4-6 hours), and does not contain preservatives to maintain RBC viability [1]. * **Sodium Fluoride:** This is an **antiglycolytic agent** used primarily for blood glucose estimation. It inhibits the enzyme enolase. It is not used for transfusion as it is toxic and does not preserve cells for long-term storage. **High-Yield Clinical Pearls for NEET-PG:** * **CPDA-1 (Citrate Phosphate Dextrose Adenine):** Currently the most common preservative. Adenine increases ATP levels, extending shelf life to **35 days**. * **SAGM (Saline Adenine Glucose Mannitol):** An additive solution that extends RBC shelf life to **42 days**. * **Citrate Toxicity:** Massive blood transfusion can lead to hypocalcemia because the citrate in the stored blood chelates the patient's calcium. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 583-584.

Question 1048: In coagulation failure, what is the serum level of fibrinogen?

A. Less than 150 mg/dL
B. Less than 100 mg/dL (Correct Answer)
C. Less than 200 mg/dL
D. Less than 250 mg/dL

Explanation: **Explanation:** **1. Understanding the Correct Answer (B):** Fibrinogen (Factor I) is a soluble plasma glycoprotein synthesized by the liver. In the final step of the coagulation cascade, thrombin converts fibrinogen into insoluble fibrin strands to form a stable clot. The normal reference range for plasma fibrinogen is **200–400 mg/dL**. **Coagulation failure** (clinically significant hypofibrinogenemia) occurs when levels drop below the critical threshold required for effective hemostasis. In the context of Disseminated Intravascular Coagulation (DIC), severe liver disease, or obstetric emergencies (like Abruptio Placentae), a level **less than 100 mg/dL** is the classic diagnostic hallmark of consumption coagulopathy [1]. At this level, the blood's ability to form a functional clot is severely compromised, leading to spontaneous hemorrhage [1]. **2. Analysis of Incorrect Options:** * **Option A (150 mg/dL):** While this is below the normal range, it is generally considered a "borderline" or mild deficiency. Most surgical procedures can still be performed safely at this level. * **Options C & D (200 & 250 mg/dL):** These values fall within the **normal physiological range**. Fibrinogen is also an acute-phase reactant; therefore, during inflammation or pregnancy, levels may actually rise above 400 mg/dL. **3. NEET-PG High-Yield Pearls:** * **Critical Level for Transfusion:** Cryoprecipitate is usually indicated when fibrinogen levels fall below **100 mg/dL** in a bleeding patient. * **Best Screening Test:** The **Thrombin Time (TT)** is highly sensitive to fibrinogen deficiency. * **DIC Profile:** Look for the triad of **low fibrinogen**, **low platelets**, and **elevated D-dimer/FDPs** [1]. * **Congenital Condition:** *Afibrinogenemia* refers to a total absence of fibrinogen, while *Dysfibrinogenemia* refers to normal levels but functional defects. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 625-626.

Question 1049: Which of the following statements is NOT true regarding Bernard-Soulier syndrome?

A. Ristocetin-induced platelet aggregation is normal. (Correct Answer)
B. Platelet aggregation with collagen and ADP is normal.
C. Platelets are large.
D. There is thrombocytopenia.

Explanation: **Explanation:** **Bernard-Soulier Syndrome (BSS)** is an autosomal recessive bleeding disorder caused by a deficiency or dysfunction of the **GPIb-IX-V complex** on the platelet surface [1]. This complex acts as the receptor for **von Willebrand Factor (vWF)**, which is essential for platelet adhesion to the subendothelial matrix [1], [2]. **Why Option A is the correct answer (The False Statement):** In BSS, because the GPIb receptor is defective, platelets cannot bind to vWF. **Ristocetin** is an agent that induces platelet aggregation by facilitating the binding of vWF to GPIb. Therefore, in BSS, **Ristocetin-induced platelet aggregation (RIPA) is characteristically absent or impaired**, and it does not correct with the addition of normal plasma (unlike von Willebrand Disease). Stating it is "normal" is incorrect. **Analysis of Incorrect Options (True Statements):** * **Option B:** Platelet aggregation in response to other agonists like **ADP, Collagen, and Epinephrine** remains **normal** because the receptors for these substances (like GPIIb/IIIa) are unaffected [1]. * **Option C:** BSS is a "Giant Platelet Disorder." On a peripheral smear, platelets are characteristically **large** (often the size of RBCs) due to abnormal megakaryocyte maturation. * **Option D:** Most patients have mild to moderate **thrombocytopenia** because the large, defective platelets have a shortened lifespan in circulation. **High-Yield Clinical Pearls for NEET-PG:** * **Triad of BSS:** Thrombocytopenia, Giant Platelets, and prolonged Bleeding Time. * **Differential Diagnosis:** In **von Willebrand Disease (vWD)**, RIPA is also abnormal, but it **corrects** when normal plasma (source of vWF) is added. In BSS, it does not correct. * **Glanzmann Thrombasthenia:** Contrast this with BSS; here, RIPA is normal, but aggregation with ADP/Collagen is defective (GPIIb/IIIa deficiency) [1], [2]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, pp. 668-669. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Hemodynamic Disorders, Thromboembolic Disease, and Shock, p. 128.

Question 1050: Which of the following is true regarding Hemophilia A?

A. Serum levels of factor VIII are decreased (Correct Answer)
B. Deficiency of factor IX
C. PT increased
D. FVIII decreased

Explanation: **Explanation:** **Hemophilia A** is an X-linked recessive bleeding disorder caused by a deficiency or functional defect of **Coagulation Factor VIII** [1], [2]. 1. **Why Option A is Correct:** In Hemophilia A, the primary pathology is the reduction in the synthesis or activity of Factor VIII [1]. Therefore, serum/plasma levels of Factor VIII are characteristically decreased. Since Factor VIII is a crucial component of the intrinsic pathway (acting as a cofactor for Factor IXa), its deficiency impairs the formation of the tenase complex, leading to a bleeding diathesis. 2. **Why Other Options are Incorrect:** * **Option B:** Deficiency of Factor IX is the hallmark of **Hemophilia B** (Christmas Disease), not Hemophilia A. * **Option C:** Prothrombin Time (PT) measures the extrinsic and common pathways (Factors VII, X, V, II, I). Since Factor VIII is part of the **intrinsic pathway**, the PT remains **normal**. The characteristic laboratory finding is a **prolonged Activated Partial Thromboplastin Time (aPTT)**. * **Option D:** While technically true, Option A ("Serum levels...") is the more precise clinical description of the laboratory finding used for diagnosis. *(Note: In some versions of this question, D might be considered a duplicate; however, A is the standard academic phrasing).* **High-Yield Clinical Pearls for NEET-PG:** * **Inheritance:** X-linked recessive (affects males; females are usually asymptomatic carriers) [2]. * **Clinical Presentation:** Characterized by **Hemarthrosis** (bleeding into joints, most commonly the knee) and deep tissue hematomas [3]. * **Mixing Study:** A prolonged aPTT in Hemophilia A will **correct** when mixed with normal plasma (distinguishing it from Factor VIII inhibitors/antibodies). * **Treatment:** Recombinant Factor VIII replacement or Desmopressin (for mild cases to release stored FVIII from Weibel-Palade bodies) [3]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, pp. 670-671. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Genetic Disorders, p. 151. [3] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 623-624.

Practice by Chapter

Anemias: Classification and Approach

Practice Questions

Hemolytic Anemias

Practice Questions

Myeloproliferative Neoplasms

Practice Questions

Myelodysplastic Syndromes

Practice Questions

Acute Leukemias

Practice Questions

Chronic Leukemias

Practice Questions

Lymphomas and Lymphoid Neoplasms

Practice Questions

Plasma Cell Disorders

Practice Questions

Bleeding Disorders

Practice Questions

Thrombotic Disorders

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free